Our results showed that elevated BCKDK and p-BCKDK (Y246) expression levels were positively associated with mCRC and negative prognosis in CRC patients, suggesting its potential role as a therapeutic target in mCRC. This evidence concerns the gene BCKDK and colorectal carcinoma.